Score Overview
PeriodNet IncomeRevenueScoreGrowthTrendConsistencyGrowthTrendConsistency
1 Year
—
20.70%
Grew
—
—
Shrank
—
1 Year
Score—
Net Growth20.70%
Net TrendGrew
Net Income Consistency—
Rev Growth—
Rev TrendShrank
Revenue Consistency—
5 Years
2.3
-7x
60%
—
-100.00%
Never
—
5 Years
Score2.3
Net Growth-7x
Net Trend60%
Net Income Consistency—
Rev Growth-100.00%
Rev TrendNever
Revenue Consistency—
Summit Therapeutics PLC fundamental performance
Between 2020 and 2025, revenue declined from £ 628.88K to £ 0.00 and net income went from -£ 38M to -£ 1.07B. Revenue increased in 0 of those 5 years; net income in 3.
Across Summit Therapeutics PLC's full reported history, from 2015 to 2025, revenue declined from £ 1M to £ 0.00 and net income went from -£ 20M to -£ 1.07B. Revenue increased in 36% of the years measured; net income in 45%.
Summit Therapeutics PLC currently holds a 5-year HDB Score of 2.3 out of 10. How the HDB Score is calculated.
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-08-12 | $ 15.10 | — |
1 Year2025-08-12 | $ 25.68 | -41.21% |
5 Years2021-08-12 | $ 7.92 | 90.66% |
10 Years2016-08-12 | $ 6.66 | 126.69% |
All Time2015-03-05 | $ 10.19 | 48.18% |
| Period | Last Price2026-08-12 | 1 Year2025-08-12 | 5 Years2021-08-12 | 10 Years2016-08-12 | All Time2015-03-05 |
|---|---|---|---|---|---|
| Price | $ 15.10 | $ 25.68 | $ 7.92 | $ 6.66 | $ 10.19 |
| Return | — | -41.21% | 90.66% | 126.69% | 48.18% |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
| Year | |||
|---|---|---|---|
| 2026 | £ 0.00 | -£ 856M | £ 690M |
| 2025 | £ 0.00 | -£ 1.07B | £ 529M |
| 2024 | £ 0.00 | -£ 176M | £ 329M |
| 2023 | £ 0.00 | -£ 482M | £ 147M |
| 2022 | £ 583.19K | -£ 65M | £ 284M |
| 2021 | £ 1M | -£ 86M | £ 53M |
| 2020 | £ 628.88K | -£ 38M | £ 48M |
| 2019 | £ 43M | £ 4M | £ 49M |
| 2018 | £ 57M | £ 10M | £ 35M |
| 2017 | £ 14M | -£ 20M | £ 28M |
| 2016 | £ 2M | -£ 21M | £ 35M |
| IPO2015 | £ 1M | -£ 20M | £ 23M |
Explore beyond SMMT
You're looking at Summit Therapeutics PLC. Members apply the same fundamental framework across all 3,860 companies we cover.
- Every HDB Score — 1, 5, 10, 20 and 30 years, plus all-time
- Revenue and Net Income Consistency for every period
- Rank all 3,860 companies by any metric, not just three
- Filter by sector and currency, and page through the whole list
- Track your holdings in a portfolio
$99/year $149 founding price
Unlock Holder Dashboard30-day money-back guarantee.
